# Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

> **NCT07224802** · — · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 372 (actual)

## Conditions studied

- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DIAGNOSTIC_TEST:** EXELiM assay (qRT-PCR validation)
- **DIAGNOSTIC_TEST:** EXELiM small RNA sequencing

## Key facts

- **NCT ID:** NCT07224802
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-21
- **Primary completion:** 2026-01-18
- **Final completion:** 2026-02-18
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224802, "Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07224802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*